BCNatal | Fetal Medicine Research Center (Hospital Clínic and Hospital Sant Joan de Déu), University of Barcelona, Barcelona 08028, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona 08036, Spain.
Exp Biol Med (Maywood). 2021 Jul;246(14):1668-1679. doi: 10.1177/15353702211003508. Epub 2021 Apr 1.
Intrauterine growth restriction affects up to 10% of all pregnancies, leading to fetal programming with detrimental consequences for lifelong health. However, no therapeutic strategies have so far been effective to ameliorate these consequences. Our previous study has demonstrated that a single dose of nutrients administered into the amniotic cavity, bypassing the often dysfunctional placenta via intra-amniotic administration, improved survival at birth but not birthweight in an intrauterine growth restriction rabbit model. The aim of this study was to further develop an effective strategy for intra-amniotic fetal therapy in an animal model. Intrauterine growth restriction was induced by selective ligation of uteroplacental vessels on one uterine horn of pregnant rabbits at gestational day 25, and fetuses were delivered by cesarean section on GD30. During the five days of intrauterine growth restriction development, three different methods of intra-amniotic administration were used: continuous intra-amniotic infusion by osmotic pump, multiple intra-amniotic injections, and single fetal intraperitoneal injection. Technical feasibility, capability to systematically reach the fetus, and survival and birthweight of the derived offspring were evaluated for each technique. Continuous intra-amniotic infusion by osmotic pump was not feasible owing to the high occurrence of catheter displacement and amnion rupture, while methods using two intra-amniotic injections and one fetal intraperitoneal injection were technically feasible but compromised fetal survival. Taking into account all the numerous factors affecting intra-amniotic fetal therapy in the intrauterine growth restriction rabbit model, we conclude that an optimal therapeutic strategy with low technical failure and positive fetal impact on both survival and birthweight still needs to be found.
宫内生长受限影响了多达 10%的所有妊娠,导致胎儿编程,对终身健康产生不利影响。然而,迄今为止,还没有有效的治疗策略来改善这些后果。我们之前的研究表明,在宫内生长受限兔模型中,通过羊膜腔内给药绕过常常功能失调的胎盘,单次给予营养物质可以提高出生时的存活率,但不能提高出生体重。本研究的目的是进一步开发一种在动物模型中进行羊膜内胎儿治疗的有效策略。在妊娠第 25 天选择性结扎子宫胎盘血管,在宫内生长受限兔模型中诱导宫内生长受限,在妊娠第 30 天通过剖宫产分娩胎儿。在宫内生长受限发展的五天期间,采用了三种不同的羊膜内给药方法:通过渗透泵持续羊膜内输注、多次羊膜内注射和单次胎儿腹腔内注射。每种技术的技术可行性、系统到达胎儿的能力以及衍生后代的存活率和出生体重均进行了评估。由于导管移位和胎膜破裂的发生率较高,渗透泵持续羊膜内输注不可行,而使用两次羊膜内注射和一次胎儿腹腔内注射的方法在技术上是可行的,但会影响胎儿的存活率。考虑到宫内生长受限兔模型中影响羊膜内胎儿治疗的诸多因素,我们得出结论,仍然需要找到一种技术失败率低且对生存和出生体重都有积极影响的最佳治疗策略。